Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ACADIA Pharmaceuticals
(NASDAQ:ACAD)
Intraday
$16.575
0.265
[1.62%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$16.575
0.265
[1.62%]
Last update: 7:05AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 12 days from now on Wed May 8th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)
ACADIA Pharmaceuticals Stock (NASDAQ: ACAD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 22, 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Accepted For Filing And Priority Review By Health Canada
Benzinga Newsdesk
-
4 days ago
Wednesday, April 17, 2024
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Benzinga Newsdesk
-
Apr 17, 2024, 4:19PM
Wednesday, April 10, 2024
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Benzinga Insights
-
Apr 10, 2024, 4:01PM
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 9:33AM
Tuesday, April 09, 2024
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 6:28AM
Monday, March 25, 2024
Expert Ratings For ACADIA Pharmaceuticals
Benzinga Insights
-
Mar 25, 2024, 10:00AM
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $25
Benzinga Newsdesk
-
Mar 25, 2024, 9:19AM
Tuesday, March 19, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Mar 19, 2024, 1:35PM
Wednesday, March 13, 2024
Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $30
Benzinga Newsdesk
-
Mar 13, 2024, 12:02PM
Tuesday, March 12, 2024
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 12, 2024, 2:07PM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30.19
Benzinga Newsdesk
-
Mar 12, 2024, 2:04PM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $30
Benzinga Newsdesk
-
Mar 12, 2024, 10:41AM
Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $37
Benzinga Newsdesk
-
Mar 12, 2024, 9:25AM
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
-
Mar 12, 2024, 9:17AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Mar 12, 2024, 9:05AM
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Lowers Price Target to $19
Benzinga Newsdesk
-
Mar 12, 2024, 8:14AM
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 12, 2024, 8:11AM
Baird Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $31
Benzinga Newsdesk
-
Mar 12, 2024, 8:00AM
B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $30
Benzinga Newsdesk
-
Mar 12, 2024, 7:26AM
Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details
Vandana Singh
-
Mar 12, 2024, 7:19AM
Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk
-
Mar 12, 2024, 7:09AM
JMP Securities Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $39
Benzinga Newsdesk
-
Mar 12, 2024, 6:48AM
HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $33 Price Target
Benzinga Newsdesk
-
Mar 12, 2024, 6:45AM
Acadia Pharmaceuticals shares are trading lower after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.
Benzinga Newsdesk
-
Mar 12, 2024, 6:44AM
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32
Benzinga Newsdesk
-
Mar 12, 2024, 5:56AM
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Avi Kapoor
-
Mar 12, 2024, 5:36AM
Mizuho Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $25
Benzinga Newsdesk
-
Mar 12, 2024, 5:27AM
Monday, March 11, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Mar 11, 2024, 5:34PM
Acadia Pharmaceuticals shares are trading lower after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.
Benzinga Newsdesk
-
Mar 11, 2024, 4:40PM
ACADIA Pharmaceuticals Shares Resume Trade
Happy Mohamed
-
Mar 11, 2024, 4:35PM
Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Mar 11, 2024, 4:30PM
Acadia Pharmaceuticals Announces Top-Line Results From Phase 3 ADVANCE-2 Trial Of Pimavanserin In Negative Symptoms Of Schizophrenia; Study Did Not Meet Primary Endpoint
Benzinga Newsdesk
-
Mar 11, 2024, 4:14PM
ACADIA Pharmaceuticals Shares Halted, News Pending
Benzinga Newsdesk
-
Mar 11, 2024, 4:01PM
Trading Halt: Halted at 4:00:53 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Mar 11, 2024, 4:00PM
Friday, March 01, 2024
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $29
Benzinga Newsdesk
-
Mar 1, 2024, 7:49AM
Wednesday, February 28, 2024
HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $33 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 12:15PM
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 11:03AM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $35
Benzinga Newsdesk
-
Feb 28, 2024, 9:47AM
Mizuho Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $39
Benzinga Newsdesk
-
Feb 28, 2024, 8:42AM
Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
Benzinga Insights
-
Feb 28, 2024, 7:00AM
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $36
Benzinga Newsdesk
-
Feb 28, 2024, 6:22AM
Tuesday, February 27, 2024
Acadia Pharmaceuticals Expects 2024 DAYBUE Net Product Sales Of $370M-$420M, NUPLAZID Net Product Sales Of $560M-$590M
Benzinga Newsdesk
-
Feb 27, 2024, 4:55PM
Recap: ACADIA Pharmaceuticals Q4 Earnings
Benzinga Insights
-
Feb 27, 2024, 4:15PM
ACADIA Pharmaceuticals Q4 2023 GAAP EPS $0.28 Misses $0.31 Estimate, Sales $231.04M Beat $223.79M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:13PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Thursday, February 15, 2024
Watching ACADIA Pharmaceuticals; Culper Research Issues Report On Co Titled "ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Daybue In The Rearview"
Benzinga Newsdesk
-
Feb 15, 2024, 11:20AM
Wednesday, February 07, 2024
JMP Securities Reiterates Market Outperform on ACADIA Pharmaceuticals, Maintains $42 Price Target
Benzinga Newsdesk
-
Feb 7, 2024, 11:33AM
Monday, February 05, 2024
Oppenheimer Reiterates Perform on ACADIA Pharmaceuticals, Maintains $25 Price Target
Benzinga Newsdesk
-
Feb 5, 2024, 8:53AM
Friday, February 02, 2024
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Benzinga Newsdesk
-
Feb 2, 2024, 10:13AM
Tuesday, January 30, 2024
Baird Initiates Coverage On ACADIA Pharmaceuticals with Outperform Rating, Announces Price Target of $40
Benzinga Newsdesk
-
Jan 30, 2024, 6:18AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch